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Burden of Cancer in Serbia
Aim To provide a comprehensive assessment of burden of 
selected cancers in Serbia.
Method We calculated disability adjusted life years (DALY) 
– the sum of the years of life lost (YLL) from premature 
mortality and the years lived with disability (YLD) – for 
cancers of stomach, colon and rectum, lung, breast, and 
cervical cancer for central Serbia and Vojvodina, Serbia and 
Montenegro. The obtained values were compared with the 
corresponding values for European region as estimated by 
the World Health Organization. The study was conducted 
between October 2002 and September 2003. The cancer 
burden was estimated for the year 2000.
Results Observed cancers were responsible for 133 689 
DALYs (73 197 for men and 60 482 for women). There 
were significantly more losses because of premature death 
than disease disability (95.2% vs 4.8% in men P<0.001, and 
93.2% vs 6.8% in females, P<0.001). The cancer burden was 
dominated by lung cancer in men and breast cancer in wom-
en. The cancer burden was very small before the age of 35.
Conclusion DALYs per 1000 population were higher in 
Serbia than in the European region for all observed cancers 
except for stomach cancer. The participation of a burden 
caused by disability in the total burden of selected cancers 
was lower in Serbia than in other European countries, with 
the greatest differences in colorectal, breast, and cervical 
cancers.
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There is growing literature on the use of sum-
mary measures of population health, which com-
bine the information on mortality and non-fatal 
health outcomes (1,2). One of them, called disabil-
ity-adjusted life years (DALY) was introduced by 
the World Bank (3) and subsequently used by the 
World Health Organization and Harvard Uni-
versity for detailed assessment of global burden of 
disease and injuries (4). Afterwards, many inves-
tigators have performed and published studies on 
burden of diseases and injuries using DALY, which 
reflect both the years of life lost because of prema-
ture death and years lived with disability (5-7).
Morbidity and mortality of cancers have a 
great impact on population of Serbia. During 
many decades, malignant neoplasms have occu-
pied the second place as a cause of death, with 
mortality rates for some cancers showing a slow 
but steady increase (8,9). In 2000, cancer account-
ed for 19% of all causes of deaths (21% in men, 
and 17% in women) in the population of Serbia 
without Kosovo and Metohia. In 2000, stomach 
cancer (International Classification of Diseases, 
version 10 [ICD10], code C16), colorectal cancer 
(ICD10 codes C18 – C21), lung cancer (ICD10 
codes C33 – C34), breast cancer (ICD10 code 
C50), and cervical cancer (ICD10 code C53) 
were responsible for 50% of all cancer incidence 
cases (45% in men and 54% in women) and for 
65% of deaths caused by all malignant neoplasms 
(63% in men, and 66% in women) (10). Lung 
cancer, colorectal cancer, and stomach cancer 
were among ten leading causes of deaths in men, 
whereas breast cancer, colorectal cancer, lung 
cancer, stomach cancer, and cervical cancer were 
among twelve leading causes of death in women 
(11). We chose these cancers to provide a com-
prehensive assessment of premature mortality 
and disability attributable to cancers in Serbia by 
calculating disability adjusted life years (DALY).
Method
The Serbian Burden of Disease Study was 
carried out by the European Agency for Recon-
struction Project Team, using methods largely 
based on those developed for the Global Burden 
of Disease study (4). The project commenced in 
October 2002 and was completed in September 
2003. The study was conducted in Central Ser-
bia and Vojvodina, Serbia and Montenegro.
The burden of selected cancers was estimat-
ed for the year 2000 by the use of DALY, which 
combines a measurement of premature mortality 
and disability (12-15). This indicator is the aggre-
gation of years of life lost (YLL) and years lived 
with disability (YLD) at the population level and 
thus reflects the “burden of disease” in a popula-
tion (DALY = YLL + YLD).
Population data
The population estimates for the calcula-
tion of values of needed indicators were based 
on the census adjustments for 2000, not in-
cluding the migration component (16). The 
total number of observed population was 
7 551 000. Direct method, with the European 
population as the standard, was used for stan-
dardization (17).
Mortality data
The Regional Offices of Statistics compile in-
formation on death certificates. The Serbian Of-
fice of Statistics receives these data from each 
region and provides a unit record file of deaths 
with diagnosis, death date, age, sex, and place of 
residence. For the burden of disease estimates, we 
considered all deaths of people with place of resi-
dence in Serbia that occurred anywhere in or out 
of Serbia and were registered in 2000.
The completeness of Serbian Office of Sta-
tistics 2000 mortality database was 98%. In ad-
dition to missing data, two other problems with 
the validity and reliability of cause of death data 
were present: not assigning a specific code but us-
ing “senility” or some other ill-defined code, and 
assigning the wrong code due to diagnostic fash-
ion or carelessness.
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According to the Global Burden of Disease 
methodology, ill-defined causes of deaths were 
reassigned. The 8.7% of deaths assigned to ill-de-
fined and senility codes (U161) were redistrib-
uted proportionally, by sex and age, across the 
group of communicable, maternal, perinatal, and 
nutritional conditions among those 0-5 years 
old, and across the group of non-communicable 
diseases among those >5 years old. Cancers of 
unspecified sites (U077), which made 3.4% of all 
deaths, were redistributed proportionally by age 
and sex across all specified sites. Finally, 0.1% of 
deaths with missing age data were redistributed 
proportionally by sex and cause.
YLL was determined by the average life ex-
pectancy at the age of death while discounting 
future years by 3%. The 3% discount rate, rec-
ommended by the International Panel on Cost 
Effectiveness in Health and Medicine (18), was 
chosen to allow for international comparisons. 
YLL were calculated by multiplying age-specific 
mortality rates by age-specific standard expected 
for YLL and population numbers. Standard ex-
pected YLL were derived from the standard life 
table West 26 (19) with a life expectancy at birth 
of 82.5 years for women. Life table West 25 (20) 
for women was used for men with life expectancy 
at birth of 80 years.
The Global Burden of Disease Study weight-
ed a year of healthy life lived at young age and 
older age lower than for other ages, because there 
is a broad social preference to value a year lived by 
a young adult more highly than a year lived by a 
young child or at older ages (4). Although not all 
investigators agree that young age and older age 
should be given less weight, in Serbian Burden of 
Disease Study 2000, we decided to use this ap-
proach to be able to compare our results with the 
results of other studies.
Incidence data
YLD was calculated on the basis of inci-
dence data. The incidence data were obtained 
from the Cancer Registry of central Serbia for 
1999 (10) and from Cancer Registry of Vojvodi-
na for 1998 (21). From data for Central Serbia, 
only those for Belgrade population were used be-
cause they were more reliable than the data for 
the rest of the region. Global Burden of Disease 
(22), Dutch study (23) models, and provisional 
disability weights for cancer stages were used for 
all cancers. Since Dutch weights do not exist for 
cervical cancer, we applied weights used in Victo-
ria study (24).
It was accepted that, according to the Global 
Burden of Disease estimate, 20% of cancers were 
untreated in the region of the former socialist 
economies of Europe (4).
For all cancers observed, including breast 
cancer, we assumed patients who survived five 
years to be in remission and we took the five-year 
survival rate as the cure rate. Patients who were 
cured were assumed to be without disability (22). 
For patients who died, average time to death was 
assumed to follow an exponential distribution, 
so that the mean survival time was estimated by 
fitting this distribution to available survival data 
(after 1, 3, and 5 years) by Kaplan-Meier product 
limit method (24,25). The duration of primary 
diagnosis, therapy, remission, and preterminal 
phase of each cancer were discussed with experts. 
The experts’ opinion was also asked for the fre-
quency of small cell and non-small cell lung can-
cer, both operable and inoperable ones, and for 
the incidence of breast cancer by size. Since there 
are no data on survival of cancer patients in Ser-
bia, we used 5-year survival data for Slovenia in 
the period 1985-1989 (26). Both Serbia and Slo-
venia had been part of former Yugoslavia before 
1991.
Results
The incidence and mortality rates for selected 
malignant neoplasms in central Serbia and Vo-
jvodina in 2000 (Table 1) were compared for re-
liability with the same data for Slovenia (27) in 
1999 (Table 2). Cancer incidence rates in these 
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two populations were similar, although the fre-
quency of lung cancer and cervical cancer was 
higher in Serbia, and the frequency of stomach 
and colorectal cancers was higher in male popu-
lation of Slovenia. The incidence was almost the 
same for breast cancer. Mortality rates of stom-
ach and colorectal cancers were similar, but mor-
tality rates for lung, breast, and cervical cancers 
were higher in Serbia.
Observed cancers were responsible for 73 197 
DALYs in men and for 60 482 DALYs in wom-
en. There were significantly more YLL than YLD 
losses for all cancers (95.2% vs 4.8% in men, and 
93.2% vs 6.8% in women), showing that the bur-
den of cancer was dominated by mortality rather 
than long-term disability (Table 3).
Lung cancer accounted for the largest part of 
the cancer burden in men, followed by colorec-
tal and stomach cancers, whereas the burden of 
breast cancer was negligible. For women, the bur-
den of breast cancer was the greatest, followed by 
lung cancer, colorectal cancer, cervical cancer, 
and stomach cancer (Table 3).
The cancer burden was very small before the 
age of 35 (Figure 1). The DALY rates per 1000 
male population were the highest in the 55-74 
age group for lung cancer and in the 65-74 age 
group for stomach and colorectal cancer. For 
women, DALY rates were the highest in the 55-
74 age group for lung cancer, and in those aged 
≥65 years for stomach and colorectal cancers. 
The burden of breast and cervical cancers was 
greater in younger age groups, ie, those aged 45-
64 years and 45-54 years, respectively.
We compared the incidence, YLD, and 
DALY per 1000 population, as well as YLD/
DALY ratio (%) of selected cancers in Serbia and 
European region divided in European subregions 
A, B, and C (Table 4). The incidence of breast 
Table 2. Incidence and mortality rates from selected cancers by 
sex in Slovenia, 1999*
Crude rate (standardized†) per 1000 population
incidence‡ mortality
Cancer site men women men women
Stomach 0.32 (0.35) 0.16 (0.12) 0.25 (0.28) 0.16 (0.11)
Colorectal 0.59 (0.63) 0.42 (0.32) 0.35 (0.38) 0.29 (0.20)
Lung 0.85 (0.86) 0.21 (0.17) 0.78 (0.80) 0.22 (0.16)
Breast 0.01 (0.01) 0.98 (0.83) 0.003 (0.003) 0.39 (0.31)
Cervical – 0.20 (0.18) – 0.05 (0.04)
All cancers 4.58 (4.77) 4.15 (3.34) 2.77 (2.95) 2.08 (1.56)
*Population of Slovenia: men – 960 456, women – 1 021 289.
†According to European population (17).
‡According to Cancer Register of Slovenia (27).
Table 1. Incidence and mortality rates from selected cancers by 
sex in Serbia, 2000*
Crude rate (standardized†) per 1000 population
incidence‡ mortality
Cancer site men women men women
Stomach 0.28 (0.24) 0.14 (0.10) 0.30 (0.25) 0.16 (0.12)
Colorectal 0.57 (0.49) 0.42 (0.32) 0.45 (0.38) 0.31 (0.22)
Lung 1.26 (0.95) 0.29 (0.23) 1.18 (0.99) 0.30 (0.22)
Breast 0.02 (0.02) 1.02 (0.83) 0.01 (0.01) 0.50 (0.40)
Cervical – 0.33 (0.29) – 0.16 (0.12)
All cancers 4.70 (4.11) 4.08 (3.24) 3.06 (2.63) 2.15 (1.62)
*Population of Serbia: men – 3 673 529, women – 3 877 326.
†According to European population (17).
‡According to data for Belgrade, 2000 (10), and Vojvodina, 1998 (21).
Table 3. Burden of selected cancers by site and sex in Serbia, 2000*
Measures of population health
Cancer site YLD YLD per 1000 YLL YLL per 1000 DALY DALY per 1000
Men:
 stomach cancer  386 0.10 10 416  2.84 10 416  2.94
 colorectal cancer  983 0.27 14 542  3.96 15 525  4.23
 lung cancer 2136 0.58 44 407 12.09 46 543 12.67
 breast cancer   56 0.02    271  0.07    327  0.09
 total 3561 0.97 69 636 18.96 73 197 19.93
Women:
 stomach cancer  198 0.05   5487  1.42   5685  1.47
 colorectal cancer  802 0.21   9680  2.49 10 482  2.70
 lung cancer  518 0.13 12 027  3.10 12 545  3.24
 breast cancer 2078 0.54 21 463  5.54 23 541  6.07
 cervical cancer  529 0.14   7701  1.99   8230  2.12
 total 4125 1.06 56 358 14.54 60 483 15.60
*Abbreviations: YLD – years lived with disability, estimated by use of Global Burden of Disease (GBD) weights (22); YLL – years of life lost; DALY – disability-adjusted 
life years.
Croat Med J 2006;47:134-141
138
cancer in Serbia was almost the same as that in 
the European region. The incidence of stom-
ach and colorectal cancers was lower and the in-
cidence of lung and cervical cancers was higher 
in Serbia. The most pronounced difference was 
found in the incidence of cervical cancer, which 
was 2.5 times higher in Serbia than in the Euro-
pean region. DALY per 1000 population in Ser-
bia was higher than in the European region for all 
observed cancers, except for stomach cancer. The 
differences between Serbia and the European 
region in participation of YLD and YLL in the 
total burden (DALY) were presented through 
YLD/DALY ratio. The proportion of YLD in 
DALY for stomach and lung cancers in Serbia 
was similar to that estimated for the European 
region. For colorectal, breast, and cervical can-
cer, the proportion of YLD in DALY was small-
er even in comparison to European B and Euro-
pean C regions.
The burden of the same cancers was also esti-
mated by Dutch weights used for calculation of 
Table 5. The burden of cancers by site in the population of Serbia and selected countries, 2000
YLD* per 1000 DALY† per 1000 YLD/DALY (%)‡
Cancer site YLD crude standardized§ DALY crude standardized§ Serbia Victoria New Zealand The Netherlands
Stomach 1246 0.17 0.14 17 149 2.27 1.92  7.0 10.0 not available not available
Colorectal 2945 0.39 0.32 27 167 3.60 2.97 11.0 20.0 18.0 not available
Lung 4192 0.55 0.52 60 626 8.03 7.89  7.0  9.0  7.0  6.5
Breast 5086 0.67 0.59 26 820 3.55 3.10 19.0 28.0 26.0 27.0
Cervical 1121 0.15 0.14   8822 1.17 1.06 13.0 19.0 not available not available
*YLD – years lived with disability; Dutch weights used for estimation of YLD (23,24).
†DALY – disability-adjusted life years.
‡Victoria (24), New Zealand (28), the Netherlands (29,30).
§Standardized according to European population (17).
Table 4. Incidence, years lived with disability (YLD)*, disability-adjusted life years (DALY) per 1000 population (all persons), and YLD/
DALY ratio from selected cancers in Serbia and European region
Region†
Cancer site Serbia European European A European B European C
Stomach cancer:
incidence 0.16‡  0.25   –  –   –
YLD 0.06‡  0.06  0.06 0.04  0.09
DALY 1.84‡  1.83  1.15 1.48  3.29
YLD/DALY (%) 3.0  3.0  5.0 3.0  3.0
Colorectal cancer:
incidence 0.39‡  0.43   –  –   –
YLD 0.20‡  0.27  0.50 0.12  0.20
DALY 2.85‡  2.14  2.63 1.30  2.49
YLD/DALY (%) 7.0 13.0 19.0 9.0  8.0
Lung cancer:
incidence 0.62‡  0.46   –  –   –
YLD 0.29‡  0.12  0.14 0.08  0.11
DALY 6.66‡  3.75  4.04 2.76  4.49
YLD/DALY (%) 4.0  3.0  3.0 3.0  2.0
Breast cancer:
incidence 0.45‡  0.42   –  –   –
YLD 0.25‡  0.36  0.50 0.18  0.27
DALY 2.76‡  2.14  2.46 1.36  2.29
YLD/DALY (%) 9.0 17.0 20.0 13.0 12.0
Cervical cancer:
incidence 0.15‡  0.06   –  –   –
YLD 0.06‡  0.05  0.03 0.05  0.06
DALY 0.98‡  0.46  0.26 0.67  0.69
YLD/DALY (%) 6.0 11.0 12.0 7.0  9.0
*Years lived with disability, estimated by use of Global Burden of Disease (GBD) weights (22).
†European region (22): European region A (very low child, very low adult mortality) – Andorra, Austria, Croatia, Czech Republic, Denmark, Finland, France, Germany, 
Greece, Iceland, Ireland, Israel, Italy, Luxemburg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzerland, United King-
dom; European region B (low child, low adult mortality): B1 – Albania, Bosnia and Herzegovina, Bulgaria, Georgia, Poland, Romania, Slovakia, The Former Yugoslav 
Republic of Macedonia, Turkey, Serbia and Montenegro; B2 – Armenia, Azerbaijan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan; European region C (low child, 
high adult mortality) – Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Republic of Moldavia, Russian Federation, Ukraine.
‡Standardized according to European population (17).
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YLD (Table 5). Since Dutch weights were much 
higher, the values of YLD and DALY were also 
higher than those obtained by Global Burden 
of Disease study weights. The same was true for 
YLD/DALY ratios. Participation of YLD in 
DALY for lung cancer in Serbia was similar to 
that found in Victoria study (24), but YLD/
DALY ratio for stomach, colorectal, breast, and 
cervical cancers in Serbia was lower.
Discussion
The total burden of lung, stomach, colorec-
tal, breast, and cervical cancers in Serbia in 2000 
amounted to 133 689 DALYs. There were sig-
nificantly more losses on account of premature 
death than disease-related disability. The partici-
pation of a burden caused by disease-related dis-
ability in the total burden of selected cancers was 
lower in Serbia than in other European coun-
tries, with the greatest differences being found 
for colorectal, breast, and cervical cancers.
Although we considered our mortality data 
reliable, percentage of deaths assigned to ill-de-
fined codes was not small. However, we could 
expect that among ill-defined causes of deaths, 
cardiovascular diseases were more frequent than 
malignant diseases.
On the basis of comparison with cancer in-
cidence in Slovenia (27), we assumed that data 
from the Cancer Register for Belgrade and for 
Vojvodina were reliable enough to estimate can-
cer incidence in Serbia. Slovenia was chosen for 
comparison for several reasons. Serbia and Slo-
venia had been part of former Yugoslavia before 
1991, the health service in Slovenia was close-
ly related to that in Serbia, and Cancer Registry 
in Slovenia was one of the oldest services of this 
type in Europe (26). With some exceptions, in-
cidence rates of observed cancers were similar in 
these two populations. Higher incidence rates of 
lung and cervical cancers in Serbia were expect-
ed, because smoking rate is one of the highest in 
Europe and screening for cervical cancer has not 
been established yet.
Method used for estimation of DALY was 
largely based on the one developed for the Glob-
al Burden of Disease study (4). After discussion 
with experts for selected cancers, the Global Bur-
den of Disease model and provisional disabili-
ty weights for cancer stages were used (22). The 
estimation of YLD by Dutch disease model and 
disability weights (23) was also performed to al-
low for comparison with other population data 
analyzed by the same method. As expected, how-
ever, we obtained similar information from these 
two models, at least when the burden of cancer 
is concerned. Only the participation of YLD in 
DALY was higher when Dutch weights were ap-
plied. In Australian Burden of Disease study (5), 
the two sets of weights were used concurrent-
ly because there was a high correlation between 
them for 54 conditions, indicating that the two 
sets of weights valued the same conditions simi-
larly. Although it is possible to create own disease 
model and to estimate own disability weights, in 
Figure 1. The burden of cancer by site, sex and age in Serbia, 
2000. Triangles – stomach cancer; open circles – colorectal can-
cer; rhombs – cervical cancer; squares – breast cancer; closed 
circles – lung cancer.
Croat Med J 2006;47:134-141
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our opinion, the same disease model and disabil-
ity weights should be used in all studies to make 
comparison between populations possible. Since 
we had no reliable data about treated and non-
treated cases, we accepted that, according to the 
Global Burden of Disease estimate, 20% of the 
cancer cases were untreated (4).
We used 5-year survival data for Slovenia 
from 1985 to 1989 (26) because it was more ap-
propriate than to use data on some other neigh-
boring country or Europe as a whole. The reason 
was that in Serbia we could not expect positive 
changes in survival during the preceding 10 years, 
ie, in the period 1991-2000. The civil strife in 
1991, which led to the war and the break-up of 
the former Yugoslavia, United Nation’s econom-
ic sanctions imposed on Serbia and Montenegro, 
and the ensuing economic crisis had a highly ad-
verse effect on the population health and the 
quality of health care (31).
We may conclude that DALYs, used as the 
summary measure of population health in the 
present study, can be considered a good esti-
mate of cancer burden in Serbia. The differenc-
es in cancer burden and especially the differences 
in YLD/DALY ratio between Serbia and Euro-
pean region, and between Serbia and Victoria, 
New Zealand, and the Netherlands, could be ex-
plained by higher incidence and/or higher fatal-
ity of almost all observed cancers in Serbia. Ear-
ly diagnosis and early and adequate therapy of 
lung cancer and to a less extent of stomach can-
cer do not influence significantly their progno-
sis. That is why YLD/DALY ratio for these can-
cers is similar both in the developed and in the 
developing countries. On the other hand, ear-
ly diagnosis and therapy of cervical, breast, and 
colorectal cancers have considerable influence on 
their outcome. Consequently, the participation 
of YLD in DALY is lower in countries like Ser-
bia, in which regular screening for these cancers 
has not been organized yet, than in countries in 
which early detection was established years ago. 
It should be also mentioned that YLD/DALY 
ratio can be affected by age distribution of the 
diseased – the participation of YLL in DALY is 
greater when fatal disease occurs in younger age 
groups.
The most important advantage from a policy 
perspective of the approach taken in this study is 
that estimates of burden of cancers are expressed 
in terms of a summary health-outcome measure, 
which combines mortality and morbidity. These 
estimates should guide future health strategies 
and interventions and would allow for monitor-
ing of the improvements in health and the per-
formance of the health care system. However, 
there are views that burden of disease assessment 
should be supplemented with positive measures 
of health expectancy or health adjusted life ex-
pectancy (HALE). According to Tobias (28), 
these two families of summary measures of popu-
lation health could be measured in such a way to 
make them not only conceptually, but also quan-
titatively complementary. In any case, the esti-
mate of disability adjusted life years for selected 
cancers should be repeated after several years in 
order to assess the effects of preventive strategies, 
which are in the process of implementation.
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